Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Key Highlights for Investors

• Continued Progress in Oncology and Rare Diseases:
  Atossa Therapeutics made significant advances in its lead candidate, (Z)-endoxifen, focusing on breast cancer and rare disease indications, notably Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS).
• FDA Designations:
  (Z)-endoxifen received both Rare Pediatric Disease (RPD) and Orphan Drug designations from the FDA for DMD, potentially accelerating FDA review and offering financial benefits, including eligibility for a Priority Review Voucher (PRV) which can be sold or transferred for between \$100–\$200 million based on recent transactions.
• Industry Recognition:
  Atossa won the 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy, underscoring its innovative work with (Z)-endoxifen.
• Strengthened Leadership Team:
  The company enhanced its clinical leadership by adding Dr. Kathy Puyana Theall (Medical Director – Breast Oncology) and Dr. Adebola Giwa (Medical Director – Rare Diseases), supporting its strategy across breast cancer and rare disease programs.

Clinical & Regulatory Developments

• DMD Opportunity:
  Atossa published a peer-reviewed article outlining the potential therapeutic role of (Z)-endoxifen in DMD, including symptomatic female carriers. The drug targets multiple disease drivers such as inflammation, fibrosis, calcium dysregulation, mitochondrial dysfunction, and lipid abnormalities. (Z)-endoxifen’s direct estrogen-receptor modulation and allosteric PKC inhibition may slow disease progression, and its pharmacology bypasses CYP2D6 metabolic variability—a limitation of tamoxifen.
• FDA Rare Pediatric Disease Designation:
  Granted in December 2025 for DMD, this designation makes Atossa eligible for a PRV upon approval, which has significant financial implications.
• FDA Orphan Drug Designation:
  Received in January 2026 for DMD, providing potential regulatory support and market exclusivity upon approval.

Financial Performance

• Operating Expenses:
  Total operating expenses for 2025 were \$37.1 million, up \$9.5 million from 2024 (\$27.6 million). This increase was primarily driven by higher clinical and non-clinical trial expenses related to (Z)-endoxifen, increased compensation, and higher professional fees.
• Research & Development (R&D):
  R&D expenses rose 50% to \$21.2 million in 2025, mainly due to increased spending on clinical trials and drug development. Compensation and professional fees also increased, reflecting expansion in headcount and regulatory consulting.
• General & Administrative (G&A):
  G&A expenses increased 18% to \$16.0 million, primarily due to higher legal fees from ongoing litigation and patent defense, and increased investor relations spending. Insurance expenses decreased due to lower premiums.
• Interest Income:
  Interest income declined to \$2.4 million from \$4.1 million, reflecting lower average funds invested.
• Impairment Charge:
  No impairment charge recorded in 2025, compared to a \$1.7 million write-down in 2024 for investment in Dynamic Cell Therapies, Inc.
• Net Loss:
  Atossa reported a net loss of \$34.8 million (\$4.04 per share) for 2025, compared to a net loss of \$25.5 million (\$3.04 per share) in 2024.
• Balance Sheet:
  Cash and cash equivalents stood at \$41.3 million at year-end 2025, down from \$71.1 million in 2024. Total assets were \$47.6 million, with total liabilities at \$8.2 million and stockholders’ equity at \$39.4 million.

Strategic Outlook & Potential Share Price Movers

• Regulatory Designations:
  The receipt of both FDA Rare Pediatric Disease and Orphan Drug designations is highly significant, as it may expedite regulatory review and confer valuable financial incentives (e.g., PRV sale).
• Pipeline Progress:
  The focus on DMD (a rare and underserved indication) with regulatory support positions Atossa for potential market exclusivity and fast-track commercialization upon successful clinical outcomes.
• Management Expansion:
  Recent hires in clinical leadership signal readiness for advancing key programs toward value-creating milestones.
• Industry Recognition:
  The R&D award reinforces Atossa’s credibility and potential for innovation in precision endocrine therapy.
• Financial Resources:
  Despite a widened net loss and reduced cash reserves, Atossa maintains a strong balance sheet with sufficient resources to continue clinical advancement.
• Litigation & Patent Defense:
  Increased legal fees and ongoing patent defense highlight potential risks but also underline the company’s commitment to protecting its intellectual property.

Product & Intellectual Property

• (Z)-Endoxifen:
  Atossa’s proprietary oral formulation is not yet approved for any indication but has demonstrated a favorable safety profile and unique pharmacology, including ER-targeted effects and PKC inhibition.
• Intellectual Property:
  The (Z)-endoxifen program is backed by a robust global IP portfolio, with multiple newly issued patents and pending applications.

Forward-Looking Statements & Risks

Atossa’s outlook includes further regulatory milestones, investigational new drug submissions, continued clinical progress, and potential commercialization. However, these are subject to risks relating to clinical timelines, regulatory approvals, patent protections, capital needs, macroeconomic factors, and ongoing litigation.

Contact Information

Investors and Media: CORE IR
Email: [email protected] | [email protected]
Phone: (212) 655-0924

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties. Investors should review Atossa Therapeutics’ filings with the SEC and consult their financial advisors before making investment decisions.

View ATOSSA THERAPEUTICS, INC. Historical chart here